Tag Archives: NASDAQ:NUVA

Cantor Fitzgerald Sticks to Its Hold Rating for NuVasive (NUVA)

Cantor Fitzgerald analyst Craig Bijou maintained a Hold rating on NuVasive (NUVA – Research Report) yesterday and set a price target of $50. The company’s shares closed on Friday at $49.55. Bijou said: “We maintain our Neutral rating and 12-month

Needham Reiterates Their Buy Rating on NuVasive (NUVA)

Needham analyst Michael Matson reiterated a Buy rating on NuVasive (NASDAQ: NUVA) today and set a price target of $75. The company’s shares closed yesterday at $62.51. Matson said: “NUVA’s 3Q18 revenue beat while its EPS missed. Management raised revenue

Cantor Fitzgerald Maintains Their Hold Rating on NuVasive (NUVA)

In a report released today, Craig Bijou from Cantor Fitzgerald maintained a Hold rating on NuVasive (NASDAQ: NUVA), with a price target of $58. The company’s shares opened today at $67.50. Bijou noted: “We maintain our Neutral rating and 12-month

Needham Reiterates a Buy Rating on NuVasive (NUVA)

Needham analyst Michael Matson reiterated a Buy rating on NuVasive (NASDAQ: NUVA) today and set a price target of $80. The company’s shares closed yesterday at $67.56. Matson noted: “We believe that new products, improved biologics growth, easing comps, and

NuVasive Receives a Hold from Cantor Fitzgerald

In a report released yesterday, Craig Bijou from Cantor Fitzgerald maintained a Hold rating on NuVasive (NASDAQ: NUVA), with a price target of $58. The company’s shares closed yesterday at $58.05. Bijou observed: “: We maintain our Neutral rating on

A Director at NuVasive (NASDAQ: NUVA) is Buying Shares

Today, a Director at NuVasive (NASDAQ: NUVA), Peter C. Farrell, bought shares of NUVA for $236.7K. Following this transaction Peter C. Farrell’s holding in the company was increased by 180.64% to a total of $1.83 million. Following Peter C. Farrell’s